2021 American Transplant Congress
Short-term Therapy with Anti-icam-1 Monoclonal Antibody Induced Long-term Liver Allograft Survival in Non-human Primates
*Purpose: Tolerance induction remains challenging following liver transplantation and the long-term use of immunosuppressants, especially calcineurin inhibitors, leads to serious complications. We aimed to test…2021 American Transplant Congress
The Relevance of Naturally Occurring Non-HLA Antibody to Antibody Mediated Rejection in Patients without Anti-HLA Antibodies After Kidney Transplantation
*Purpose: Very few papers describe the association between non-HLA antibodies and the incidence of antibody mediated rejection (AMR) in kidney recipients. We investigated the incidence…2021 American Transplant Congress
A Comparison of Plasmapheresis Methods in the Treatment of Late Antibody Mediated Rejection
*Purpose: Effective management to prevent allograft loss after late antibody mediated rejection (ABMR) in kidney transplant (KTx) recipients remains a vexing clinical challenge. While plasma…2021 American Transplant Congress
Desensitization with Plasmapheresis and IV Immunoglobulin is Safe and Effective in Pra Positive Kidney Transplant Recipient Candidates in Covid-19 Pandemic Period
*Purpose: High panel reactive antibody (PRA) levels may limit living-donor kidney transplantation (LDKT) according to increased risk of antibody mediated rejection. Desensitization may provide better…2021 American Transplant Congress
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
*Purpose: To evaluate development of de novo donor specific antibodies (dnDSA) in Renal Transplant Recipients (RTR) with immunosuppression (IS) modulation due to BK viremia (BKV)…2021 American Transplant Congress
Evaluation of Rituximab-abbs in Renal Transplant: A Case Series
*Purpose: Biosimilars are FDA-approved alternatives to cost-prohibitive biologics, with no clinically meaningful differences in safety, purity, and potency. Rituximab-abbs, a biosimilar to rituximab, has labeled…2021 American Transplant Congress
Systematic Screening of Kidney Transplant Patients Points Towards Deficits in Neutralizing Antibody Capacity Against Sars-cov-2
*Purpose: The majority of kidney transplant recipients (KTR) is able to develop SARS-CoV-2 antibodies (Abs). Little is known about the virus neutralizing capacity of these…2021 American Transplant Congress
Successful Prophylaxis of Antibody-Mediated Rejection by Downregulation of C5 Expression via RNA Interference in a Rat Kidney Transplant Model
*Purpose: Antibody-mediated rejection (AMR) is a major contributor towards poor prognosis in kidney transplantation. Circulating donor-specific antibodies (DSAs) cause AMR with complement activation. This study…2021 American Transplant Congress
A2 to B Deceased Donor Renal Transplantation Outcome Analysis: Single Center Experience
Nephrology, University of Michigan, Ann Arbor, MI
*Purpose: Initial experience under kidney allocation system (KAS) implemented in December 2014 showed equivalent outcomes for A2 to B kidney transplantation compared with ABO compatible…2021 American Transplant Congress
Development and Durability of Sars-cov-2 Antibodies Among Solid Organ Transplant Recipients
*Purpose: The response to SARS-CoV-2 may be blunted in transplant recipients, impacting reinfection risk, treatment selection, and vaccine protocols. We quantified antibody response and durability…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 57
- Next Page »